Tuesday, September 19, 2017

Visited Purdue University Today

I visited Dr. Susie Swithers' Drugs and Behavior class at Purdue University today and introduced the students to forensic toxicology. Had some good interactions with the students. I have fun with things like this - love outreach and education.

While you're reading this, why not peruse Purdue's Psychological Sciences website and learn something new?

Forensic Toxicology Job Listings

Some good job opportunities are out there for forensic toxicology!

The following are good references and sites for job postings:

Society of Forensic Toxicologists - Job Listings

American Academy of Forensic Sciences - Job Postings

Midwestern Association of Forensic Scientists - Employment

Southwestern Association of Forensic Scientists - Employment

Northeastern Association of Forensic Scientists - Employment

Tuesday, September 12, 2017

Three more fentanyl analogs to be placed into Schedule I

The DEA announced today a notice of intent to place three more fentanyl analogs into Schedule I of the Controlled Substances Act. These compounds are Methoxyacetylfentanyl, Ortho-Fluorofentanyl, and Tetrahydrofuranfentanyl. 

According to the Federal Register, the first detection of Ortho-Fluorofentanyl in drug seizure evidence was in April 2016 and the first detection of Tetrahydrofuranfentanyl was in March 2017. Methoxyacetylfentanyl was first identified in solid dose evidence in April 2017. There have been multiple confirmed fatalities associated with each of these substances.

These three compounds make a total of nine (9) fentanyl analogs controlled by the DEA since 2015. Others controlled in this time period are Acetylfentanyl (2015), Betahydroxthiofentanyl and Butyrylfentanyl, and Furanylfentanyl (2016), and 4-Fluorisobutyrylfentanyl and Acrylfentanyl(2017).


References

United States DEA (2017) Notice of Intent. Schedules of Controlled Substances: Temporary Placement of Orthofluorofentanyl, Tetrahydrofuranylfentanyl, and Methoxyacetylfentanyl
 into Schedule I. Federal Register. Volume 82, Number 175.
https://www.gpo.gov/fdsys/pkg/FR-2017-09-12/pdf/2017-19283.pdf

Monday, September 11, 2017

Synthetic cannabinoid FUB-AMB to be placed into Schedule I

The DEA announced today a notice of intent to place the synthetic cannabinoid FUB-AMB into Schedule I of the Controlled Substances Act.

The chemical formula of FUB-AMB is C21H22FN3O3 and molecular weight is 383.42 g/mol. Alternative alphabet soup names for this substances include AMB-FUBINACA and MMB-FUBINACA. FUB-AMB emerged as a substance in herbal incense and smokable potpourri blends in the USA sometime between 2014-2016. FUB-AMB is structurally related to the Pfizer developed synthetic cannabinoid AB-FUBINACA. In 2016, Banister et al. reported on the pharmacology of FUB-AMB and structurally related compounds. They determined FUB-AMB to be a potent synthetic cannabinoid receptor agonist. In the study, FUB-AMB's half maximal effective concentration or EC50 at CB1 equaled 2.0 nM and 18 nM at CB2.

Image taken by Kevin G. Shanks (2017)


A "mass casualty event" in Brooklyn, New York occurred on July 12, 2016, when thirty three (33) people reported adverse effects after smoking an herbal incense product. Eighteen (18) of the 33 people were hospitalized. Adams et al. reported on this outbreak of illnesses in The New England Journal of Medicine on January 2017. Common reported effects included blank stares, slow responses, "zombielike" groaning, slow mechanical movements of the arms and legs, and lethargy. Blood, serum, and urine specimens were obtained from eight (8) of the people who were admitted to the hospital. The authors also analyzed a package of the product purported to be at the center of the mass illnesses - AK-47 24 Karat Gold. FUB-AMB was detected in the product. An FUB-AMB metabolite was detected in the blood or serum of all patients tested.

This act makes 33 synthetic cannabinoids scheduled at the federal level since 2011.

One more synthetic cannabinoid scheduled, one more to take its place.

The beat goes on...


References

United States DEA (2017) Notice of Intent. Schedules of Controlled Substances: Temporary Placement of FUB-AMB into Schedule I. Federal Register. Volume 82, Number 174.
https://www.deadiversion.usdoj.gov/fed_regs/rules/2017/fr0911.htm

S.D. Banister et al. (2016) Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience. 7: 1241-1254.
http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00137

A.J. Adams et al. (2017) Zombie Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York. The New England Journal of Medicine. 376: 235-242.
http://www.nejm.org/doi/10.1056/NEJMoa1610300

Tuesday, September 5, 2017

DEA Emerging Threat Report - Mid-Year 2017

The DEA has released their emerging threat report for mid-year 2017. It is located here via the National Drug Early Warning System (NDEWS).

In summary...

No new synthetic cannabinoids have been identified US drug seizures in 2017. FUB-AMB remains the most commonly identified synthetic cannabinoid with 5F-MDMB-PINACA and ADB-FUBINACA running second and third.

Fentanyl remained the most prevalent opioid detected with furanylfentanyl and U47700 running second and third. Fentanyl analogs methoxyacetylfentanyl and tetrahydrofuranfentanyl were identified for the first time in drug evidence in the US during this time period. Interestingly, with as much coverage as carfentanil has gotten from media reports, it was only fifth in the overall number of detections. Maybe that's a good thing?

The top two cathinones detected were N-ethylpentylone and dibutylone. N-ethylpentylone made up approximately 50% of all cathinone drug detections. Alpha-PVP has fallen to fourth in the list, but it is still out there.

Only two pieces of evidence were identified as NBOMe hallucinogens (25C-NBOMe and 25I-NBOME).

Tryptamines remain inconsequential in drug seizure evidence.


Other DEA emerging trend reports for 2016 and 2017 can be found here.


Reference

Drug Enforcement Administration. Emerging Threat Report. Midyear 2017.
https://ndews.umd.edu/sites/ndews.umd.edu/files/dea-emerging-threat-report-2017-mid-year.pdf

Saturday, September 2, 2017

Fentanyl and analogs are now the leading drug-related cause of death

This report from the New York Times shows that fentanyl and analogs have overtaken heroin as the leading drug-related cause of death in the USA, which is not at all surprising if you've been paying attention to these over the last few years.
 
But it is frightening, and as the article points out, the numbers from 2016 are not even final and will more than likely go -up-. Another terrifying aspect to this is that fentanyl analog related deaths are most likely underreported as testing for said analogs is really in its infancy and not every known analog can be (or is) accounted for in toxicological testing. Not every postmortem toxicology case includes fentanyl analogs in the scope of testing, whereas heroin (detected in blood and urine as 6-acetylmorphine and morphine) and fentanyl are routinely covered in even the most basic postmortem toxicology testing panels.
 
To make matters even more dire, all signs point to increasing fentanyl/analog death numbers in 2017.

As I've said for a while now, this ain't your father's heroin. At what point do we stop calling it heroin and refer to the standard "heroin" product on the street as fentanyl?
 
It is also interesting to note that cocaine is making a comeback. Or the better realization may be that it never really went away. Cocaine related deaths have continued to rise over the last few years and have more than doubled since about 2010-2011. From this data set beginning in the year 2000, cocaine related deaths peaked in 2005-2006 and then trended downward until 2010 when they began to increase again. Cocaine deaths reached an all time high (topping the peak set in 2005-2006) in 2015-2016.
 
 
Reference

Josh Katz. New York Times. Fentanyl Overtakes Heroin as Leading Cause of US Drug Deaths. 09/02/2017.
https://www.nytimes.com/interactive/2017/09/02/upshot/fentanyl-drug-overdose-deaths.html?smid=tw-share

Wednesday, August 30, 2017

Counterfeit Oxycodone Tablets in Indiana: Fentanyl and Carfentanil (May 2017)

In May 2017, the Indianapolis Metro Police Department (IMPD) seized 970 "oxycodone" tablets that were colored light and dark blue. The laboratory analyzed the "oxycodone" tablets and identified them as counterfeit / illicitly manufactured. The lighter blue tablets were presumptively positive for fentanyl and the darker blue tablets were presumptively positive for carfentanil. Confirmatory analyses were not completed.

 
 
Chemical structures drawn by KGS (2017)



The detailed account of the seizure as well as pictures of the tablets can be found in the following web link to the DEA's website.

Fake RX in Indiana: Carfentanil and Fentanyl Found in Purported Oxycodone Pills